Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spleen surgery and kidney health: a hidden connection in cirrhosis?

NCT ID NCT07811713

Knowledge-focused Sponsor: Northern Jiangsu People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

People with liver cirrhosis and portal hypertension often have kidney problems because of reduced blood flow and fluid buildup. Researchers at one hospital are reviewing medical records of patients who had laparoscopic splenectomy and azygoportal disconnection, a minimally invasive surgery that removes the spleen and ties off swollen veins. They will track kidney function using eGFR and other markers before surgery and at 3, 6, 9, and 12 months after. The goal is to see whether kidney function changes over time and which factors, like ascites, might predict recovery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
laparoscopic splenectomy and azygoportal disconnection, a minimally invasive surgery that removes the spleen and ties off swollen veins
What this could lead to
If the surgery is linked to better kidney function, doctors could use that pattern to guide care for cirrhotic patients with portal hypertension. It may also help identify which patients are most likely to recover kidney function.
What could go wrong
This study only reviews past medical records, so it cannot prove the surgery causes any kidney changes. Kidney function may shift for other reasons, and the findings from one hospital may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

496 people

The number who actually took part.

Started

Feb 2012

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This is a retrospective, single-center, observational cohort study. The study population consists of adult patients with liver cirrhosis, splenomegaly and hypersplenism, and portal hypertension bleeding who underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at the Department of Hepatobiliary Surgery, Subei People's Hospital Affiliated to Yangzhou University between February 2012 and February 2025. Patients were identified from electronic medical records and followed for up to 12 months postoperatively to assess renal function dynamics. The study aimed to evaluate the effect of LSD on renal function recovery and identify factors associated with postoperative renal outcomes in this high-risk population.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years. 2. Diagnosis of liver cirrhosis with portal hypertension. 3. Underwent laparoscopic splenectomy and azygoportal disconnection (LSD) at our institution. 4. Adequate preoperative and postoperative clinical and follow-up data for analysis. 5. Preoperative and postoperative eGFR data available at the specified time points (baseline, month 3, 6, 9, and 12). Exclusion Criteria: 1. Child-Pugh Class C liver cirrhosis. 2. Primary renal diseases (e.g., glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.). 3. Previous abdominal surgery that precluded safe laparoscopic splenectomy and azygoportal disconnection (LSD). 4. Severe cardiac, pulmonary, or cerebrovascular dysfunction; malignant tumors; or primary hematological disorders. 5. Hepatic encephalopathy or refractory ascites within 1 month before surgery. 6. Pregnancy or lactation. 7. Poor compliance or inability to complete follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis, liver are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis portal hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis, liver Portal hypertension Renal function abnormal Splenectomy; status

More trials for these conditions

Other studies related to the condition(s) this trial covers.